1. Introduction {#s0005}
===============

Nanotechnology is the mere controlling and fabrication of materials at nano scale level, where characteristics vary with altered size, shape, density, aggregation and surface area. This technological leap leads to a revolution in the field of electronics and communications, optics, chemistry, energy and biology ([@b0145]). Nanotechnology is a rapidly expanding field with an estimated market of \$75.8 billion by 2020 ([www.reportlinker.com/april2015](http://www.reportlinker.com/april2015){#ir005}). IONPs have promising characteristics like biocompatibility and magnetic behaviour that makes them good agents for magnetic resonance imaging, carriers for drug delivery, magnetic hyperthermia, tissue engineering, cell separation, enzyme immobilization, protein purification and biosensing ([@b0095], [@b0140]). IONPs are also used in many analytical techniques like PCR, immunoassay, HPLC and LC MS/MS ([@b0030]). Moreover, IONPs offer significant improvements in water purification and environmental remediation because of low cost technology ([@b0025]).

New approaches in nanotechnology and extensive production for numerous diversified applications of nanomaterials (NMs) might increase human exposure. A recent study on mice by [@b0175], reported size dependent bioaccumulation and transport of IONPs in the liver and spleen. Further, expression of genes associated with antioxidant defence system, transport and metabolism of iron were reported when treated with IONPs. Pregnant mice treated with multiple doses of IONPs reported biodistribution of iron in the foetal liver, placenta and increased foetal deaths ([@b0050]). Intratracheal instillation studies of IONPs in mice reported increased cell disruption in the respiratory epithelium and affected haemostasis ([@b0185]). Initiation of microglial proliferation and pathological alterations in the brain was observed in mice treated with IONPs by intranasal route ([@b0165]). IONPs induced higher levels of inflammation and immunosuppression in mice ([@b0020]). This shows that IONPs can easily cross the intestinal lining and can enter into systemic circulation where it accumulates in different organs.

*In vivo* and *in vitro* studies of different NMs reported generation of free radicals and oxidative injury is the key mechanism to instigate adverse effects on cellular functions ([@b0015]). Overloading of cells with IONPs may trigger inimical cellular effects by initiating the fenton chemistry, which generates free radicals ([@b0150]). Cells have antioxidant defence system to intercept the reactive oxygen species (ROS), however if the biological systems fail to nullify the overwhelming ROS, it will lead to oxidation of biomolecules like proteins, DNA and lipids ([@b0130]). Several studies demonstrated oxidative stress as an important biomarker in assessing NMs toxicity ([@b0060], [@b0125], [@b0130], [@b0105], [@b0010]).

In the present investigation, the physicochemical properties of IONPs were determined using X-ray Diffraction (XRD), Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS). The purpose of the current study was to assess the differences in exerting toxic effects between IONPs and bulk after repeated oral treatment to Wistar rats. The liver, kidney and the brain were selected for our study, to investigate the oxidative stress induced by IONPs and its bulk using biomarkers like reduced glutathione (GSH), malondialdehyde (MDA), antioxidant enzymes catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S transferase (GST). The histopathological analysis was done to detect tissue damage, if any. Biodistribution studies were undertaken to identify the potential target site of accumulation of IONPs and bulk.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

Fe~2~O~3~-bulk materials size of \<5 μm (CAT \#310050, purity ⩾99%), iron standard (CAT \#43149) and all chemicals were purchased from Sigma Aldrich Inc., USA.

2.2. Synthesis and characterization of IONPs {#s0020}
--------------------------------------------

IONPs were produced by chemical coprecipitation method following the method of [@b0075]. The purity of IONPs was performed according to the method given by [@b0180]. The spectra analysis of IONPs was obtained using Siemens/D-5000 X-ray diffractometer. The size and morphology of IONPs were characterized using TEM (Hitachi H-7600). Hydrodynamic size distribution and zeta potential of IONPs were measured using Malvern Zetasizer. Probe sonicator (UP100H Heilscher, Germany) was used to disperse the NMs. Dispersion of NMs in the solution is measured by the polydispersity index (PDI).

2.3. Animals and treatment {#s0025}
--------------------------

According to the OECD (Organization for Economic Cooperation and Development) guidelines, the preferred rodent species is the rat, preferably females because of their sensitivity in comparison to males. Hence, female rats were used in our study. Institutional Animal Ethics Committee (IICT, Hyderabad) approved the present investigation. Female albino wistar rats of 8--10 weeks were procured from the National Institute of Nutrition, Hyderabad, India. Animals were acclimatized under standard laboratory conditions for 7 days prior to the start of experiments. The animals were fed on commercial pellet diet and water *ad libitum*.

The animals were randomly selected, marked and divided into following groups:GroupCompoundDosageControlWater--LowNano30 mg/kg b.w.MediumNano300 mg/kg b.w.HighNano1000 mg/kg b.w.LowBulk30 mg/kg b.w.MediumBulk300 mg/kg b.w.HighBulk1000 mg/kg b.w.The rats were treated daily with IONPs and bulk for 28 days and sacrificed on the 29th day after being anesthetized. The study and dose design were according to [@b0115]. High dose was chosen to illustrate the lethal effects and symptoms without mortality, whereas the low dose was selected to demonstrate no observed adverse effect levels (NOAEL). The animals were checked for toxic symptoms and mortality (if any) every day, whereas, weight gain and feed intake were recorded once in a week.

2.4. Oxidative stress biomarkers {#s0030}
--------------------------------

Lipid peroxidation (LPO) in rat organs was estimated according to the method described by [@b0170]; reduced glutathione ([@b0065]); superoxide dismutase ([@b0100]); catalase ([@b0005]); glutathione peroxidase ([@b0120]); glutathione reductase ([@b0035]); glutathione S transferase ([@b0055]) and detailed procedures were described in [@b0135]. The protein estimation was done using [@b0085] method.

2.5. Analysis of iron content in tissues {#s0035}
----------------------------------------

A part of the liver, kidney, and the brain from each group was collected at the end of the study. Individual urine and faecal samples were collected daily and pooled, analysed for the metal content following standard procedures as described in our earlier publication [@b0135]. ICP-OES (IRIS Intrepid II XDL, Thermo Jarrel Ash) was used to quantify Fe concentration at alternate wavelengths (232 nm and 238 nm). Quantification of Fe was done using a calibration curve.

2.6. Histopathological study {#s0040}
----------------------------

The liver, kidney and the brain collected from each rat were fixed in 10% formalin and processed following standard procedures. Detailed protocol was described in [@b0135].

2.7. Data analysis {#s0045}
------------------

All the data were expressed as mean ± standard deviation (SD). Graphpad prism 5, a statistical software system was used to perform a post hoc multiple comparison test (Dunnet's test) after ANOVA. *P* \< 0.05 was considered to be significant.

3. Results {#s0050}
==========

3.1. Characterization {#s0055}
---------------------

[Fig. 1](#f0005){ref-type="fig"} summarizes the characterization of IONPs by XRD, TEM and DLS. The purity analysis by ICP-OES revealed that the purity of IONPs was \>96%. This analysis was in support of XRD data obtained. Peaks obtained signify size, purity and crystallinity of IONPs and revealed similar characteristics with γ-Fe~2~O~3~. TEM characterization of IONPs showed spherical morphology with mean size distribution of 7.02 ± 1.58 nm. The hydrodynamic sizes of IONPs were measured using DLS in MilliQ water showed an average diameter of 155 nm with a PDI measurement of 0.526. These hydrodynamic sizes in dispersion vehicle were larger than their original size in powder form signifying nanoparticles agglomeration. Zeta potential measurements for IONPs were −29.9 mV at pH 7. For bulk material size distribution intensity was found to be beyond detection limits.Figure 1Characterization of IONPs by (A) XRD, (B) TEM, (C) size distribution and (D) zeta potential.

3.2. Morphology, feed intake and body weight of animals {#s0060}
-------------------------------------------------------

[Fig. 2](#f0010){ref-type="fig"} represents body weight (A) and feed intake (B) of animals treated with IONPs and bulk. Signs of toxicity and mortality were not seen in the treated rats. However, rats treated with a high dose of bulk and IONPs showed significant loss in body weight in weeks 3 and 4. Average feed intake per animal was significantly decreased in high dose IONPs treated rats in comparison to other treatment groups and control.Figure 2(A) Effect of IONPs and its bulk on body-weight profile. (B) Effect of IONPs and its bulk on feed intake profile. Each value represents the mean ± SD; *n* = 5 rats.

3.3. Oxidative stress biomarkers {#s0065}
--------------------------------

The effect of IONPs and bulk on LPO in the liver, kidney and the brain is presented in [Fig. 3](#f0015){ref-type="fig"}A. IONPs and bulk treatment caused significant and a dose dependent increase in MDA levels in the liver at high and medium doses. Only high dose of IONPs and bulk increased LPO level in kidney and the brain. IONPs treated rats showed increased MDA levels than the bulk. The changes in GSH content in different tissues of treated and control rats are summarized in [Fig. 3](#f0015){ref-type="fig"}B. IONPs and bulk brought dose dependent depletion in GSH content of the liver, except low dose group of bulk material. However, IONPs at 1000 mg/kg b.w. and 300 mg/kg b.w. and bulk at 1000 mg/kg b.w. significantly decreased GSH content in kidney and the brain. Furthermore, depletion in GSH content was found high in IONPs treated rats than its bulk. High and medium dose of IONPs and bulk treatment caused significant and dose dependent inhibition of SOD in liver. However, 1000 mg/kg b.w. treatment of IONPs and bulk caused depletion in SOD activity in kidney and the brain([Fig. 4](#f0020){ref-type="fig"}A). A significant and dose dependant elevation in activity of CAT was observed in the liver, when rats were treated with IONPs and bulk at 1000 mg/kg b.w. and 300 mg/kg b.w. Similarly statistically significant increase in CAT activity was observed in kidney and the brain after the treatment of IONPs and bulk at 1000 mg/kg b.w. ([Fig. 4](#f0020){ref-type="fig"}B). IONPs and bulk treatment at 1000 mg/kg b.w. elevated GPx activity significantly only in the liver and kidney. The activity of GPx was not altered in the brain at all the doses of IONPs and bulk treatment ([Fig. 4](#f0020){ref-type="fig"}C). GR activity was significantly elevated in the liver in a dose dependent manner after IONPs treatment at 300 mg/kg b.w. and 1000 mg/kg b.w. However, bulk treatment at 1000 mg/kg b.w. increased GR activity only in the liver. Further, significant change in activity of GR was observed in kidney and the brain at mg/kg b.w. of IONPs and bulk treatment ([Fig. 4](#f0020){ref-type="fig"}D). Treatment of IONPs and bulk at 1000 mg/kg b.w. caused a substantial increase in GST activity in the liver, kidney and the brain ([Fig. 4](#f0020){ref-type="fig"}E). Antioxidant enzymes SOD, CAT, GPx, GR and GST were modulated significantly in IONPs treated rats than its bulk.Figure 3MDA (A) and GSH (B) levels in rats treated with IONPs and bulk for 28 days. Each value represents the mean ± SD; *n* = 5 rats. ^∗^*P* \< 0.05.Figure 4Effect of 28 day oral treatment of IONPs and Bulk on antioxidant enzyme activities in rat organs. Each value represents the mean ± SD; *n* = 5 rats. ^∗^*P* \< 0.05.

3.4. Analysis of iron content in tissues {#s0070}
----------------------------------------

A dose dependant increase in accumulation of Fe content was seen in the liver (188 μg/g, 224 μg/g, 303.9 μg/g), followed by kidney (58.8 μg/g, 67.4 μg/g, 88 μg/g) and the brain (28.6 μg/g, 38.3 μg/g, 45.8 μg/g) in IONPs treated rats. Similarly uptake of bulk was high in the liver (151.5 μg/g, 178.5 μg/g, 191.2 μg/g) followed by kidney (49.2 μg/g, 57.3 μg/g, 65.2 μg/g) and the brain (28 μg/g, 30.8 μg/g, 37.5 μg/g). However, accumulation of IONPs in organs was higher than bulk. Elimination of Fe through urine was found to be more significant in IONPs (65.3 μg/ml, 74.6 μg/ml, 83.6 μg/ml) treated group than bulk (51.2 μg/ml, 59.2 μg/ml, 68.3 μg/ml). In contrary, in faeces bulk (2390 μg/g, 8849.7 μg/g, 11072.4 μg/g) was eliminated more in comparison to IONPs (1116.7 μg/g, 3233.5 μg/g, 5366.9 μg/g) as shown in [Fig. 5](#f0025){ref-type="fig"}A.Figure 5Metal content analysis in tissues of treated rats after 28 days repeated treatment with IONPs and bulk material. Each value represents the mean ± SD; *n* = 5 rats. ^∗^*P* \< 0.05.

3.5. Histopathological study {#s0075}
----------------------------

The histopathological changes in IOPNs and bulk treated the liver, kidney and the brain are presented in [Fig. 6](#f0030){ref-type="fig"}. Only high dose treatment of IONPs caused congested portal tract in liver whereas, normal histology was observed in the remaining groups of IONPs and bulk.Figure 6Photomicrographs of various organs of rats after 28 day repeated oral treatment with IONPs and bulk material. Upper panel represents normal architecture of the liver, kidney and the brain from control rats. Lower panel represents the liver, kidney and the brain from high dose group treated with IONPs, congested portal tract in the liver pointed by arrow. Observation was made at 40× magnification.

4. Discussion {#s0080}
=============

Nanotoxicological studies performed *in vivo* using different routes of exposure hold greater impact in evaluating the adverse biological effects. In the present investigation, we hypothesized oxidative stress as a crucial parameter in IONPs induced toxicity in treated rats. The current study illustrates that the MDA levels were increased in tissues in a dose dependent manner in both IONPs and bulk treated rats. Elevated levels of MDA indicate the formation of hydroxyl radicals which in turn is associated with LPO of tissues. Our results illustrated a dose dependent depletion of reduced glutathione (GSH) after IONPs and bulk treatment, possibly due to enhanced utilization of GSH in both enzymatic and non-enzymatic reactions. [@b0155] reported elevated LPO and depleted GSH in rat lung tissue after inhalation exposure of IONPs. Similarly, oral toxicity study of aluminium oxide NMs and bulk demonstrated elevated levels of MDA and decreased GSH levels in a dose dependant manner in the liver, kidney and the brain of treated rats ([@b0130]). Hence, it is suggested that MDA and GSH contents are good biomarkers in assessing toxicity, which may be possibly due to free radical generation.

Individual antioxidant enzymes play different strategies to counter act oxidant insult. In this study, a significant increase in CAT, GR, GPx, GST and decrease in SOD activity in treated rat tissues were observed. Superoxide radicals in association with adventitious metal like Fe, triggers the oxidative damage of proteins, lipids and nucleic acids ([@b0040]). Current study revealed a dose dependent decrease in SOD activity in rat organs. This might probably be due to the heavy influx of superoxide radicals that in turn resulted in high levels of H~2~O~2~ generation, which subsequently inhibited SOD activity ([@b0080]b). IONPs and bulk treatment caused elevation in enzyme kinetics of CAT as a defensive mechanism against excess H~2~O~2~ levels. GPx initiates H~2~O~2~ breakdown only at low concentrations, whereas CAT needs high levels of H~2~O~2~ to commence its activity. An increased GR activity was found in our study, this result reflects the recycling of oxidized GSH to reduced GSH by the pro-oxidant system which involves a coupled reaction engaged by GR ([@b0110]). Elevated GST activity and depleted GSH levels suggest increased utilization of GSH in conjugation reactions as part of detoxification mechanism. Altered antioxidant status as reported in our study is supported by findings from other investigations. [@b0130] reported increased enzyme activities of CAT and GST, with depleted SOD activity in rat tissues exposed to aluminium oxide NMs. Administration of TiO~2~ NMs to mice for 14 days induced significant oxidative stress than its bulk ([@b0090]). An altered antioxidant status revealed imbalance in oxidant and antioxidant levels in the tissues.

In the present study ICP-OES analysis revealed that IONPs and bulk material were absorbed and extensively deposited in the liver, kidney and the brain, and excreted through urine and faeces. [@b0160] reported accumulation of IONPs in major systemic organs of mice at an oral dose of 600 mg/kg b.w., which is in support of our results. In the current investigation, IONPs with a hydrodynamic size of 155 nm and with a charge of −29.9 mV were readily taken by liver for phagocytosis, which clearly indicates size and charge also influence the uptake and clearance mechanisms. Our results demonstrated that uptake of IONPs was more in the liver, kidney and the brain in a dose dependent manner. The IONPs have differential organ distribution pattern which seems to be influenced by Fe binding proteins like transferrin and ferritin, which serve as carrier of Fe to different tissues. Increased Fe levels in brain in the present investigation might be due to binding of Fe to transferrin, that triggers up regulation of Fe receptors in the brain, thus transporting Fe across the blood brain barrier ([@b0045]). Inhalation exposure study in mice demonstrated that IONPs \<50 nm reached the brain without provoking any adverse effects ([@b0070]). Higher localization of IONPs in liver might have caused histopathological changes, causing congestion in portal tract. However, histological changes were not observed in kidney and the brain of both the treated groups. A dose dependant and significant amount of IONPs was eliminated in urine. Trace amount of bulk passed through the intestinal epithelium and remaining being excreted in faeces. However, IONPs excreted in faeces were less than the bulk.

Taken together, the findings from the current investigation, confirm that IONPs accumulation in tissues triggered ROS generation, which significantly altered the antioxidant enzyme levels. The altered antioxidant status and bioaccumulation of IONPs caused histomorphological changes, which demonstrate that increase in oxidative stress affects the cellular structure. Moreover, the results of this study can be utilized by the regulatory bodies in defining safety limits for the usage of IONPs in biomedical applications.

Conflict of interest {#s0085}
====================

The authors declare that there are no conflicts of interest.

The work was financially supported by Department of Biotechnology, New Delhi, India (Project No. BT/PR9998/NNT/28/84/2007). The authors Utkarsh A. Reddy and P.V. Prabhakar thanks Indian Council of Medical Research, New Delhi, India for awarding senior research fellowship.

Peer review under responsibility of King Saud University.
